Hypersensitivity from Intravenous Iron Products
Hypersensitivity from Intravenous Iron Products
复制标题
DOI：
10.1016/j.iac.2014.04.013
复制
发表时间：
2014-08-01
影响因子：
2.6
通讯作者：
Auerbach, Michael
中科院分区：
文献类型：
--
作者：
Bircher, Andreas J.;Auerbach, Michael
在过去的几年里，使用铁产品的静脉内治疗已经得到了更广泛的应用。尽管自20世纪90年代初以来，它一直是透析相关贫血的标准程序，但其使用正在扩展到与缺铁相关的许多疾病，特别是子宫大量出血和怀孕的年轻女性。游离铁与不可接受的高毒性相关，诱导严重的血流动力学显著症状。随后，设计了含有铁作为铁碳水化合物纳米颗粒的制剂。使用新的制剂，包括低分子量右旋糖酐铁、蔗糖铁、葡萄糖酸铁、ferumoxytol、异麦芽糖苷铁和羧基麦芽糖铁，严重不良事件很少。
In the last several years, intravenous therapy with iron products has been more widely used. Although it has been a standard procedure in dialysis-associated anemia since the early 1990s, its use is expanding to a host of conditions associated with iron deficiency, especially young women with heavy uterine bleeding and pregnancy. Free iron is associated with unacceptable high toxicity inducing severe, hemodynamically significant symptoms. Subsequently, formulations that contain the iron as an iron carbohydrate nanoparticle have been designed. With newer formulations, including low-molecular-weight iron dextran, iron sucrose, ferric gluconate, ferumoxytol, iron isomaltoside, and ferric carboxymaltose, serious adverse events are rare.